Inhibrx Biosciences (INBX) Total Current Liabilities (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Total Current Liabilities for 3 consecutive years, with $33.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Current Liabilities fell 17.02% year-over-year to $33.8 million; the TTM figure through Dec 2025 stood at $33.8 million (down 17.02% YoY), while the FY2025 annual figure was $33.8 million, down 17.02% from the prior year.
• Total Current Liabilities eased to $33.8 million in Q4 2025 per INBX's latest filing, from $36.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $56.3 million in Q4 2023 and bottomed at $33.8 million in Q4 2025.
• Historically, Total Current Liabilities has averaged $41.6 million across 3 years, with a median of $39.9 million in 2024.
• Annual changes were most pronounced in 2024 — Total Current Liabilities slipped 27.67% — and 2025, when it retreated 0.29%.
• Inhibrx Biosciences' Total Current Liabilities stood at $56.3 million in 2023, then retreated by 27.67% to $40.7 million in 2024, then declined by 17.02% to $33.8 million in 2025.
• Business Quant data shows INBX's Total Current Liabilities at $33.8 million in Q4 2025, $36.0 million in Q3 2025, and $38.9 million in Q2 2025.